Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
Selective blockade of the interleukin-23 receptor with the targeted oral peptide icotrokinra resulted in a significantly higher incidence of skin clearance at week 16 than placebo among adults and adolescents with moderate-to-severe plaque psoriasis. Longer-term data will provide a more complete understanding of the benefit-risk profile of icotrokinra. (Funded by Johnson & Johnson; ICONIC-LEAD ClinicalTrials.gov number, NCT06095115.)See also in <i>NEJM Evidence</i>: Targeted Oral Peptide Icotrokinra for Psoriasis Involving High‑Impact Sites.
Authors
- Jingzhi Jiang
- Jennifer Soung (ORCID: https://orcid.org/0009-0009-5586-0677)
- Andreas Pinter (ORCID: https://orcid.org/0000-0002-1330-1502)
- Andrew Pink (ORCID: https://orcid.org/0000-0001-5151-5539)
- Robert Bissonnette (ORCID: https://orcid.org/0000-0001-5927-6587)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Fabio P. Nunes (ORCID: https://orcid.org/0000-0002-8833-2223)
- Adelaide A. Hebert (ORCID: https://orcid.org/0000-0002-9167-5729)
- Cynthia Marie Carver DeKlotz (ORCID: https://orcid.org/0000-0002-6410-8710)
- Angela Moore (ORCID: https://orcid.org/0000-0002-5788-7445)
- Wenhui Wang (ORCID: https://orcid.org/0000-0001-6681-1373)
- Shu Li (ORCID: https://orcid.org/0000-0003-3164-1348)
- Yuling Shi
- Joseph Cafone
- Darryl Toth
- Megan Miller-Kassamali
Institutions
- Goethe University Frankfurt (DE)
- Tongji University (CN)
- University of North Texas (US)
- Texas Christian University (US)
- Johnson & Johnson (United States) (US)
- University of North Texas Health Science Center (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Peking University (CN)
- UCLA Medical Center (US)
- Baylor University Medical Center (US)
- Probity Medical Research (CA)
- University Hospital Frankfurt (DE)
- Johnson & Johnson (Israel) (IL)
- Innovaderm (Canada) (CA)
- Peking University Third Hospital (CN)
- Shanghai Skin Disease Hospital (CN)
- XLV Diagnostics (Canada) (CA)
- Arlington Center for Dermatology (US)
- Beijing Haidian Hospital (CN)
- Harbor–UCLA Medical Center (US)
- The University of Texas Medical Branch at Galveston (US)
- The University of Texas Health Science Center at Houston (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1056/nejmoa2504187
- Citations
- 9
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 7.18